Company news
Evofem Biosciences, Inc. (OTC:EVFM) news
Evofem Biosciences, Inc. news releases on 6ix. Latest, Sep 23, 2026: Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global…
Press releases & updates
Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy
September 23, 2026
Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex
July 23, 2026
HUB Cyber Security Expands Into Women’s Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet Turnaround
July 1, 2026
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
May 18, 2026
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
April 27, 2026
Evofem Reports Fifth Consecutive Year of Net Sales Growth
March 11, 2026
Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women’s Health at Fierce JPM Week 2026
January 23, 2026
Evofem CEO Saundra Pelletier Calls for a "Ground-Up Reset" of Women’s Health at Fierce JPM Week 2026
January 23, 2026
Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store
January 21, 2026
Evofem Expands "Say Vagina" Campaign With Launch of Say Vagina Store
January 21, 2026
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
November 21, 2025
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
November 13, 2025
Evofem Announces Voting Results from Special Meeting of Stockholders
October 20, 2025
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
October 1, 2025
Evofem Biosciences Honors World Contraception Day
September 26, 2025
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
September 11, 2025
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
September 9, 2025
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
August 21, 2025
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
August 19, 2025
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
August 14, 2025
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
August 5, 2025
Phexxi -- A Non-Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy
July 15, 2025
Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
June 26, 2025
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store
June 23, 2025
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting
June 11, 2025
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
May 21, 2025
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
April 15, 2025
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
April 14, 2025
Evofem Biosciences to Present at Emerging Growth Conference
April 14, 2025
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
March 26, 2025
Evofem Reports Fourth Consecutive Year of Net Sales Growth
March 24, 2025
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
March 19, 2025
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO
February 12, 2025
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
December 11, 2024
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
November 13, 2024
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
November 7, 2024
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
November 5, 2024
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
November 5, 2024
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
October 29, 2024
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
October 28, 2024
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
October 27, 2024
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
October 20, 2024
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
October 7, 2024
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
October 2, 2024
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
September 23, 2024
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
September 19, 2024
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
September 8, 2024
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
August 28, 2024
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
August 19, 2024